Erik Nelson, PhD, Professor at the University of Illinois Urbana-Champaign and Basic Science Chair for ENDO 2026, highlighted research involving cholesterol regulation and the evolution of GLP-1/GIP agonist therapies for diabetes and obesity. He also discussed their reported cardiovascular benefits and other areas of ongoing investigation. Micah Eimer, MD, General Cardiologist at Northwestern Medicine in Chicago, presented a study examining hypotension among patients who initiated GLP-1–based therapy while taking antihypertensive medications. His observations highlight the importance of monitoring low blood pressure, falls, and fainting in this clinical setting.

Dr. Luke Laughlin (Preventive Cardiologist, Cleveland Clinic) presented the Cardinal trial at ACC 2026, where Tonlamarsen, an investigational antisense oligonucleotide, reduced angiotensinogen by 67% with ongoing dosing and maintained 23% suppression after a single dose. Despite biochemical differences, both groups achieved similar ~7 mmHg systolic BP reductions, suggesting BP lags behind RAAS suppression. The upcoming Cardinal-ASH study will target acute severe hypertension patients to further evaluate its impact.

Cardiac catheterization remains a cornerstone of cardiovascular care, supporting both diagnostic evaluation and interventional management across a wide range of heart conditions. Although the procedure is inherently invasive, its safety profile has improved substantially over time due to advances in technique, imaging, device technology, and coordinated, team-based care. One of the most impactful developments has been the increased adoption of transradial access.

Compared with transfemoral (groin) access, the transradial (wrist) approach is associated with lower rates of bleeding and vascular complications, earlier ambulation, and improved patient comfort. These benefits have contributed to shorter hospital stays and broader use of same-day discharge protocols in appropriately selected patients.

Highlights:

• Cardiac catheterization is performed more than one million times annually in the United States for indications including coronary artery disease, arrhythmias, and valvular heart disease.

• Transradial access has demonstrated favorable safety and patient-centered outcomes compared with transfemoral access in many clinical settings.

• Major complications are uncommon in diagnostic procedures (<1%) but may include stroke (0.05%–0.1%), myocardial infarction (<0.1%), and contrast-associated acute kidney injury, reported in approximately 7% of cases.

• Access site–related events such as hematoma or radial artery occlusion (~5%) are generally manageable with appropriate patient selection, technique, and preprocedural assessment.

• Use of ultrasound guidance and targeted risk mitigation—such as hydration strategies for kidney protection and premedication for contrast hypersensitivity—further enhance procedural safety.

What Sets This Study Apart:

This synthesis highlights the evolving safety profile of cardiac catheterization while emphasizing evidence supporting transradial access. It integrates procedural data, complication trends, and multidisciplinary strategies that help optimize outcomes across diverse patient populations.

Limitations:

Despite ongoing improvements, individuals with significant comorbidities—including chronic kidney disease, left ventricular dysfunction, or acute coronary syndromes—remain at higher procedural risk. Operator experience and consistent adherence to evidence-based protocols continue to influence outcomes.

How do your post-catheterization protocols address renal risk and bleeding surveillance in higher-risk patients?

Heart failure (HF) remains a leading cause of morbidity and mortality, but timely initiation and optimization of guideline-directed medical therapy (GDMT) can meaningfully improve outcomes. In patients with HFrEF, comprehensive quadruple therapy—including a RAAS inhibitor, beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor—can reduce mortality by over 70%. Trials such as STRONG-HF have demonstrated that early, in-hospital or post-discharge uptitration lowers rehospitalization and death rates.

Comorbidities—particularly the cardiovascular–kidney–metabolic overlap—complicate management but highlight the need for individualized care. RAAS inhibitors reduce intraglomerular pressure and proteinuria. SGLT2 inhibitors decrease glucose reabsorption and myocardial stress, benefiting patients with or without diabetes. Nonsteroidal MRAs may also reduce renal decline and cardiovascular events in patients with type 2 diabetes and CKD. Therapy decisions must consider renal function, potassium levels, and blood pressure.

Risk stratification with tools such as LVEF, NT-proBNP, and NYHA class can guide therapy intensity and follow-up. For example, elevated NT-proBNP levels post-GDMT initiation are prognostic and can help refine monitoring strategies.

Multidisciplinary HF programs—including pharmacist-led titration, digital tools, and remote monitoring—can reduce readmissions by up to 40% and mortality by 25%.

How can your team best use pharmacist-led or digital titration to accelerate GDMT optimization in HFrEF? What strategies have been effective in overcoming therapeutic inertia and improving adherence?

Dr. Joanna Chikwui, Chief of Cardiac Surgery at Cedars-Sinai and Chair of AHA Scientific Sessions, spotlighted significant breakthroughs across cardiology. Updates included novel therapies for hyperlipidemia, gene-editing tools for inherited cardiovascular risk, innovations in atrial fibrillation management, and compelling lifestyle findings—including a surprising inverse relationship between moderate coffee intake and AF incidence.

Dr. Heidi May, Epidemiologist at Intermountain Health, presented results from the Target-D randomized trial, which found that personalized vitamin D dosing after myocardial infarction significantly reduced the risk of recurrent heart attack. These findings underscore the importance of individualized supplementation strategies and signal a broader shift toward precision prevention and risk stratification in cardiovascular care.

Share your thoughts